#1

Reading this protocol is a nice summary of evidence to date for the use of Rapamycin to treat/prevent Alzheimer’s. I couldn’t find that someone else had posted this study protocol that came out in April 2024.

7 Likes
Genetics, phenotype, Aging "Style," rapamycin
Rapamycin as a preventive intervention for Alzheimer’s disease in APOE4 carriers: targeting brain metabolic and vascular restoration
#2

Very interesting, thanks for posting. As an ApoE4 homozygote I’m keeping my fingers crossed that rapamycin has a positive effect

2 Likes
#3

This study will provide us longevity types a fair bit of information when it’s completed.

It’s design is very close to what many use as a longevity intervention and it has a lot of good references for those who are new to Rapa.

1 Like
#4

Any preliminary results so far? They must be in the end stages at this point.

#5

Nice reference, thanks for posting this. I wish they’d be a bit more aggressive or target to blood levels on this study. Hopefully they are using coated tablets and having them take with fatty foods. 6 months is a short time, but the biomarker approach is certainly a decent surrogate for disease progression.

1 Like